JPH04504119A - ブタクサからのアレルゲン蛋白質およびそれらの使用 - Google Patents
ブタクサからのアレルゲン蛋白質およびそれらの使用Info
- Publication number
- JPH04504119A JPH04504119A JP2504838A JP50483890A JPH04504119A JP H04504119 A JPH04504119 A JP H04504119A JP 2504838 A JP2504838 A JP 2504838A JP 50483890 A JP50483890 A JP 50483890A JP H04504119 A JPH04504119 A JP H04504119A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- ragweed
- isolated
- pollen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 85
- 102000004169 proteins and genes Human genes 0.000 title claims description 80
- 230000002009 allergenic effect Effects 0.000 title claims description 23
- 244000036975 Ambrosia artemisiifolia Species 0.000 title claims description 20
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 title claims description 20
- 235000003484 annual ragweed Nutrition 0.000 title claims description 17
- 235000006263 bur ragweed Nutrition 0.000 title claims description 17
- 235000003488 common ragweed Nutrition 0.000 title claims description 17
- 235000009736 ragweed Nutrition 0.000 title claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 239000013566 allergen Substances 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 108020004414 DNA Proteins 0.000 claims description 47
- 150000001413 amino acids Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 229960004784 allergens Drugs 0.000 claims description 25
- 239000009342 ragweed pollen Substances 0.000 claims description 25
- 206010020751 Hypersensitivity Diseases 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- 230000009257 reactivity Effects 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 3
- 208000030961 allergic reaction Diseases 0.000 claims description 3
- 108091005601 modified peptides Proteins 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 10
- 229940024606 amino acid Drugs 0.000 claims 10
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 230000003915 cell function Effects 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 229940046528 grass pollen Drugs 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 108700032051 Ambrosia artemisiifolia Amb a I Proteins 0.000 claims 1
- 240000005499 Sasa Species 0.000 claims 1
- 239000012503 blood component Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 claims 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 53
- 244000055702 Amaranthus viridis Species 0.000 description 53
- 235000004135 Amaranthus viridis Nutrition 0.000 description 53
- 235000009344 Chenopodium album Nutrition 0.000 description 53
- 235000005484 Chenopodium berlandieri Nutrition 0.000 description 53
- 235000009332 Chenopodium rubrum Nutrition 0.000 description 53
- 239000002299 complementary DNA Substances 0.000 description 47
- 125000003275 alpha amino acid group Chemical group 0.000 description 37
- 238000002360 preparation method Methods 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 23
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 22
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 22
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 22
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 22
- 239000000284 extract Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 12
- 230000000172 allergic effect Effects 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 208000010668 atopic eczema Diseases 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000002751 oligonucleotide probe Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 101001123526 Ambrosia artemisiifolia Pectate lyase 4 Proteins 0.000 description 7
- 241000283707 Capra Species 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010048908 Seasonal allergy Diseases 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108700005084 Multigene Family Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 2
- 235000005490 Chenopodium botrys Nutrition 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101800000135 N-terminal protein Proteins 0.000 description 2
- 101800001452 P1 proteinase Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 244000021671 Trianthema portulacastrum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 239000013573 pollen allergen Substances 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 102100032392 Circadian-associated transcriptional repressor Human genes 0.000 description 1
- 101710130150 Circadian-associated transcriptional repressor Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 240000005066 Euchiton japonicus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101150093511 GAPC gene Proteins 0.000 description 1
- 101150115724 GAPC1 gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003678 bronchial smooth muscle cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (34)
- 1.ブタクサ花粉の単離されたアレルゲン性ペプチド。
- 2.該ブタクサがアンブロシア・アルテミシイフォリアI(Ambrosia artemisiifolia I)である請求の範囲1の単離ペプチド。
- 3.それが投与された、ブタクサに敏感な個体において、ブタクサ花粉に対する アレルギー反応を修正し得る請求の範囲1の単離ペプチド。
- 4.ブタクサアレルゲンに対するB細胞応答、ブタクサアレルゲンに対するT細 胞応答、或はこれらの両方を修正し得る請求の範囲3の単離ペプチド。
- 5.抗ブタクサIgEと結合し得る請求の範囲1の単離ペプチド。
- 6.AmbaIの単離されたアレルゲン性ペプチド。
- 7.下記のアミノ酸配列:W E N F K[ここで、 Wは、アミノ酸であるトリプトファンを表し、Eは、アミノ酸であるグルタミン 酸を表し、Nは、アミノ酸であるアスパラギンを表し、Fは、アミノ酸であるフ ェニルアラニンを表し、そしてKは、アミノ酸であるリジンを表す] で構成されている請求の範囲6の単離ペプチド、或はその機能的同等物。
- 8.a) EFPILGGITEVKDNDNSVDFC;b) YTVTSD KDDDVANC;c) GKADWAENRC; d) LENGAIFVASGVDPVLTPEQ;e) GFFQVVNNN YDRWGTYAから成る群から選択されるアミノ酸配列を有する請求の範囲6 の単離ペプチド。
- 9.アレルギー反応を防止し得る請求の範囲6の単離ペプチド。
- 10.抗ブタクサIgEと結合し得る請求の範囲6の単離ペプチド。
- 11.AmbaIの単離されたアレルゲン性ペプチド。
- 12.図11中に示すようなAmbaIAのアミノ酸配列;図12中に示すよう なAmbaIBのアミノ酸配列;図13中に示すようなAmbaICのアミノ酸 配列;および図14中に示すようなAmbaIDのアミノ酸配列:から成る群か ら選択されるアミノ酸配列の全てまたは一部を有する請求の範囲11の単離ペプ チド。
- 13.図15中に示すようなAmhaIIのアミノ酸配列の全てまたは一部を有 する単離ペプチド。
- 14.ブタクサに敏感な個体に投与されたとき、この個体のブタクサ花粉に対す るアレルギー反応を減少させるところの修飾されたブタクサ花粉ペプチド。
- 15.天然に存在している相当する花粉ペプチドよりも少ない副作用をもたらす 請求の範囲14の修飾されたブタクサ花粉ペプチド。
- 16.修飾されたAmbaIペプチドである請求の範囲15の修飾されたブタク サ花粉ペプチド。
- 17.修飾されたAmbaIIである請求の範囲14の修飾されたブタクサ花粉 ペプチド。
- 18.ブタクサ花粉のアレルゲン性蛋白質の全てもしくは一部、ブタクサ花粉の アレルゲン性ペプチドの全てもしくは一部をコード化する単離DNA、或は上記 DNAいずれかの機能的同等物。
- 19.短いブタクサ花粉のアレルゲン性蛋白質の全てもしくは一部、短いブタク サ花粉のアレルゲン性ペプチドの全てもしくは一部をコード化する請求の範囲1 8の単離DNA、或は上記DNAいずれかの機能的同等物。
- 20.AmhaIのアレルゲン性蛋白質の全てもしくは一部、AmbaIのアレ ルゲン性ペプチドの全てもしくは一部をコード化する単離DNA、或は上記DN Aいずれかの機能的同等物。
- 21.図11中に示すようなAmbaIAのヌクレオチド配列;図12中に示す ようなAmhaIBのヌクレオチド配列;図13中に示すようなAmbaICの ヌクレオチド配列;および図14中に示すようなAmbaIDのヌクレオチド配 列;から成る群から選択されるヌクレオチド配列を有する請求の範囲20の単離 DNA。
- 22.下記のアミノ酸配列:W E N F K[ここで、 Wは、アミノ酸であるトリプトファンを表し、Eは、アミノ酸であるグルタミン 酸を表し、Nは、アミノ酸であるアスパラギンを表し、Fは、アミノ酸であるフ ェニルアラニンを表し、そしてKは、アミノ酸であるリジンを表す] を有するペプチドをコード化する請求の範囲20の単離DNA、或はその機能的 同等物。
- 23.a) EFPILGGITEVKDNDNSVDFC;b) YTVTS DKDDDVANC;c) GKADWAENRC; d) LENGAIFVASGVDPVLTPEQ;e) GFFQVVNNN YDRWGTYAから成る群から選択されるアミノ酸配列を有するペプチドをコ ード化する請求の範囲20の単離DNA。
- 24.図15中に示すようなAmbaIIのヌクレオチド配列の全てまたは一部 のヌクレオチド配列を有する単離DNA。
- 25.AmbaIのアレルゲン性ペプチドに対して特異的な反応性を示す単クロ ーン抗体。
- 26.AmbaIIのアレルゲン性ペプチドに対して特異的な反応性を示す単ク ローン抗体。
- 27.個体に対して治療学的に有効な量で、AmhaIのアレルゲン性蛋白質も しくはアレルゲン性ペプチド、或はAmbaIの免疫抗原的に修飾した蛋白質も しくは免疫抗原的に修飾したペプチドを投与することから成る、個体中のブタク サ花粉に対する敏感性の治療方法。
- 28.個体に対して治療学的に有効量の請求の範囲5のペプチドを投与すること から成る、個体中のAmbaIペプチドに対する敏感性の治療方法。
- 29.AmhaIのアレルゲン性ペプチドを含む治療学的組成物。
- 30.請求の範囲14の修飾されたブタクサ花粉ペプチドを含む治療学的組成物 。
- 31.請求の範囲1のペプチドの有効量を個体に投与した後、上記ペプチドに対 する該個体中のアレルギー反応の発生を測定することから成る、ブタクサ花粉ア レルゲンに対する個体中の敏感性を検出する方法。
- 32.血液成分とペプチドとが結合するに適当な条件下で、個体から得た血液サ ンプルとブタクサ花粉の単離アレルゲン性ペプチドとを一緒にした後、上記結合 が生じる度合を測定することから成る、ブタクサ花粉アレルゲンに対する個体中 の敏感性を検出する方法。
- 33.T細胞機能、T細胞増殖、B細胞機能の評価、該ペプチドと血液中に存在 している抗体との結合、或はそれらの組み合わせで、結合が生じる度合を測定す る請求の範囲32の方法。
- 34.B細胞によって認識されるか或はT細胞によって認識されるアミノ酸配列 を有するペプチドを個体に投与しそしてこのB細胞またはT細胞による認識が、 それぞれ、B細胞応答を下方修正するか或はT細胞応答を下方修正することから 成る、ブタクサに敏感な個体中のブタクサアレルゲンに対するアレルギー反応を 修飾し得るブタクサ花粉ペプチドの設計方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32536589A | 1989-03-17 | 1989-03-17 | |
US325,365 | 1989-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04504119A true JPH04504119A (ja) | 1992-07-23 |
JP3220451B2 JP3220451B2 (ja) | 2001-10-22 |
Family
ID=23267582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50483890A Expired - Lifetime JP3220451B2 (ja) | 1989-03-17 | 1990-03-09 | ブタクサからのアレルゲン蛋白質およびそれらの使用 |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP0463059B1 (ja) |
JP (1) | JP3220451B2 (ja) |
AT (1) | ATE175209T1 (ja) |
CA (1) | CA2049921C (ja) |
DE (1) | DE69032868D1 (ja) |
WO (1) | WO1990011293A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500194A (ja) * | 2008-08-15 | 2012-01-05 | サーカッシア リミテッド | Il−10産生の刺激のためのアレルゲン由来のt細胞抗原 |
JP2015078218A (ja) * | 2007-02-13 | 2015-04-23 | ビオマイ アクチエンゲゼルシャフト | ブタクサ(アンブロシアアルテミシーフォリア)の主要アレルゲンから得られるペプチドおよびこれらの使用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776761A (en) * | 1989-03-17 | 1998-07-07 | Immulogic Pharmaceutical Corporation | Nucleic acids encoding allergenic proteins from ragweed |
AT401180B (de) * | 1990-08-13 | 1996-07-25 | Biomay Biotech Prod | Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung |
US6555116B1 (en) * | 1991-10-12 | 2003-04-29 | Regents Of The University Of California | Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
US6441157B1 (en) | 1991-11-15 | 2002-08-27 | University Of Melbourne | Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon |
AU2926492A (en) * | 1991-11-15 | 1993-06-15 | University Of Melbourne, The | Protein allergens of the species cynodon dactylon |
CA2117779A1 (en) * | 1992-04-09 | 1993-10-28 | Mei-Chang Kuo | T cell epitopes of the major allergens from ambrosia artemisifolia |
GB2349463B (en) | 1996-03-21 | 2001-01-10 | Circassia Ltd | Cryptic peptides and method for their identification |
EP2153841B2 (en) | 2008-08-15 | 2015-11-11 | Circassia Limited | Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy |
CN107184971A (zh) | 2010-04-30 | 2017-09-22 | 艾洛维特有限责任公司 | 经由口腔粘膜变应性脱敏的方法、制品和试剂盒 |
EP2563390A4 (en) | 2010-04-30 | 2014-05-14 | Allovate Llc | METHOD AND ARTICLE FOR PREVENTING OR REDUCING THE RISK OF DEVELOPING A HYPERALGENIC IMMUNE SYSTEM |
-
1990
- 1990-03-09 WO PCT/US1990/001310 patent/WO1990011293A1/en active IP Right Grant
- 1990-03-09 DE DE69032868T patent/DE69032868D1/de not_active Expired - Lifetime
- 1990-03-09 CA CA002049921A patent/CA2049921C/en not_active Expired - Lifetime
- 1990-03-09 EP EP90905020A patent/EP0463059B1/en not_active Revoked
- 1990-03-09 EP EP96202477A patent/EP0803511A1/en not_active Ceased
- 1990-03-09 AT AT90905020T patent/ATE175209T1/de not_active IP Right Cessation
- 1990-03-09 JP JP50483890A patent/JP3220451B2/ja not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015078218A (ja) * | 2007-02-13 | 2015-04-23 | ビオマイ アクチエンゲゼルシャフト | ブタクサ(アンブロシアアルテミシーフォリア)の主要アレルゲンから得られるペプチドおよびこれらの使用 |
JP2012500194A (ja) * | 2008-08-15 | 2012-01-05 | サーカッシア リミテッド | Il−10産生の刺激のためのアレルゲン由来のt細胞抗原 |
Also Published As
Publication number | Publication date |
---|---|
CA2049921C (en) | 2004-06-15 |
DE69032868D1 (de) | 1999-02-11 |
EP0463059A1 (en) | 1992-01-02 |
CA2049921A1 (en) | 1990-09-18 |
ATE175209T1 (de) | 1999-01-15 |
EP0463059B1 (en) | 1998-12-30 |
EP0803511A1 (en) | 1997-10-29 |
WO1990011293A1 (en) | 1990-10-04 |
JP3220451B2 (ja) | 2001-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cunningham et al. | Molecular analysis of human cardiac myosin-cross-reactive B-and T-cell epitopes of the group A streptococcal M5 protein | |
US8003382B2 (en) | Nucleic acid molecules encoding a house dust mite allergen Der f VII, and antigenic peptides thereof | |
CA2073045C (en) | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor | |
JP2003500015A (ja) | モノクローナル抗体、抗原ならびに悪性疾患の診断および治療 | |
EP0763059B1 (en) | Recombinant allergen, fragments thereof, corresponding recombinant dna molecules, vectors and hosts containing the dna molecules, diagnostic and therapeutic uses of said allergens and fragments | |
Petersen et al. | Structural investigations of the major allergen Phl p I on the complementary DNA and protein level | |
JPH04504119A (ja) | ブタクサからのアレルゲン蛋白質およびそれらの使用 | |
JPH06508994A (ja) | 日本杉花粉からのアレルゲン性蛋白質及びペプチド | |
JP2000507232A (ja) | 慢性関節リウマチの病理発生に必要な関節炎誘発性ペプチドに対して免疫防御を誘発するために有用なワクチン組成物と方法 | |
JPH07505365A (ja) | 耐性の誘導に有用なペプチド | |
US5698204A (en) | Recombinant allergenic proteins from ragweed pollen | |
JPH02479A (ja) | snRNP−A抗原及びそのフラグメント | |
AU604087B2 (en) | Primary biliary cirrhosis autoantigen | |
JP3649460B2 (ja) | スギ花粉アレルゲンCry j IIエピトープ | |
KR19990071959A (ko) | 말라세지아에서 유래된 항원성 단백질 | |
JP2006051019A (ja) | Me−5、me−2、及びepp2:子宮内膜症に罹患している女性の血清中に存在する自己抗体と反応するヒト蛋白質抗原 | |
JP2005503113A (ja) | ブタクサアレルゲン | |
CA2154379A1 (en) | Parietaria allergens | |
WO1992016554A1 (en) | Protein allergens of the species cynodon dactylon | |
JPH07502648A (ja) | シノドン・ダクチロン(Cynodon dactylon)種のタンパク質のアレルゲン | |
JP2900571B2 (ja) | スギ花粉症治療剤 | |
JP4176820B2 (ja) | スギ花粉アレルゲンCryjIIエピトープ | |
JPWO2003099869A1 (ja) | 8−ニトログアニンを認識する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070810 Year of fee payment: 6 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070810 Year of fee payment: 6 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080810 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090810 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090810 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 9 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 9 |